Literature DB >> 20528878

Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia.

Carol D Jones, Sally Arai, Robert Lowsky, Dolly B Tyan, James L Zehnder, David B Miklos.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20528878      PMCID： PMC2935248          DOI： 10.1111/j.1365-2141.2010.08252.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  9 in total

1.  Real-Time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma.

Authors:  M Ladetto; J W Donovan; S Harig; A Trojan; C Poor; R Schlossnan; K C Anderson; J G Gribben
Journal:  Biol Blood Marrow Transplant       Date:  2000       Impact factor: 5.742

2.  Protective conditioning for acute graft-versus-host disease.

Authors:  Robert Lowsky; Tsuyoshi Takahashi; Yin Ping Liu; Sussan Dejbakhsh-Jones; F Carl Grumet; Judith A Shizuru; Ginna G Laport; Keith E Stockerl-Goldstein; Laura J Johnston; Richard T Hoppe; Daniel A Bloch; Karl G Blume; Robert S Negrin; Samuel Strober
Journal:  N Engl J Med       Date:  2005-09-29       Impact factor: 91.245

3.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

Authors:  T J Hamblin; Z Davis; A Gardiner; D G Oscier; F K Stevenson
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

Review 4.  Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse.

Authors:  Michael A Pulsipher; Peter Bader; Thomas Klingebiel; Laurence J N Cooper
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

Review 5.  Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.

Authors:  J A Pérez-Simón; D Caballero; M Diez-Campelo; R Lopez-Pérez; G Mateos; C Cañizo; L Vazquez; B Vidriales; M V Mateos; M Gonzalez; J F San Miguel
Journal:  Leukemia       Date:  2002-08       Impact factor: 11.528

6.  TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors.

Authors:  Holbrook E Kohrt; Brit B Turnbull; Kartoosh Heydari; Judith A Shizuru; Ginna G Laport; David B Miklos; Laura J Johnston; Sally Arai; Wen-Kai Weng; Richard T Hoppe; Philip W Lavori; Karl G Blume; Robert S Negrin; Samuel Strober; Robert Lowsky
Journal:  Blood       Date:  2009-05-07       Impact factor: 22.113

7.  Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation.

Authors:  Lucia Farina; Cristiana Carniti; Anna Dodero; Antonio Vendramin; Anna Raganato; Francesco Spina; Francesca Patriarca; Franco Narni; Fabio Benedetti; Attilio Olivieri; Paolo Corradini
Journal:  Haematologica       Date:  2009-04-18       Impact factor: 9.941

8.  Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial.

Authors:  M Ritgen; S Böttcher; S Stilgenbauer; D Bunjes; J Schubert; S Cohen; A Humpe; M Hallek; M Kneba; N Schmitz; H Döhner; P Dreger
Journal:  Leukemia       Date:  2008-04-17       Impact factor: 11.528

9.  Dynamics in chimerism of T cells and dendritic cells in relapsed CML patients and the influence on the induction of alloreactivity following donor lymphocyte infusion.

Authors:  H Levenga; R Woestenenk; A V Schattenberg; F Maas; J H Jansen; R Raymakers; P H M De Mulder; E van de Wiel-van Kemenade; N Schaap; T de Witte; H Dolstra
Journal:  Bone Marrow Transplant       Date:  2007-07-16       Impact factor: 5.483
  9 in total
  5 in total

Review 1.  Translational studies in hematopoietic cell transplantation: treatment of hematologic malignancies as a stepping stone to tolerance induction.

Authors:  Samuel Strober; Thomas R Spitzer; Robert Lowsky; Megan Sykes
Journal:  Semin Immunol       Date:  2011-06-25       Impact factor: 11.130

2.  Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival.

Authors:  Philip A Thompson; Francesco Stingo; Michael J Keating; William G Wierda; Susan M O'Brien; Zeev Estrov; Celina Ledesma; Katayoun Rezvani; Muzaffar Qazilbash; Nina Shah; Simrit Parmar; Uday Popat; Paolo Anderlini; Nieto Yago; Stefan O Ciurea; Partow Kebriaei; Richard Champlin; Elizabeth J Shpall; Chitra M Hosing
Journal:  Br J Haematol       Date:  2017-03-14       Impact factor: 6.998

3.  Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.

Authors:  Christine E Ryan; Bita Sahaf; Aaron C Logan; Susan O'Brien; John C Byrd; Peter Hillmen; Jennifer R Brown; Martin J S Dyer; Anthony R Mato; Michael J Keating; Samantha Jaglowski; Fong Clow; Andrew R Rezvani; Lori Styles; Steven E Coutre; David B Miklos
Journal:  Blood       Date:  2016-11-01       Impact factor: 22.113

4.  Rapid complete donor lymphoid chimerism and graft-versus-leukemia effect are important in early control of chronic lymphocytic leukemia.

Authors:  Brian C Shaffer; Marko Modric; Maryalice Stetler-Stevenson; Diane C Arthur; Seth M Steinberg; David J Liewehr; Daniel H Fowler; Robert P Gale; Michael R Bishop; Steven Z Pavletic
Journal:  Exp Hematol       Date:  2013-05-18       Impact factor: 3.084

5.  Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence.

Authors:  Sally Arai; Bita Sahaf; Balasubramanian Narasimhan; George L Chen; Carol D Jones; Robert Lowsky; Judith A Shizuru; Laura J Johnston; Ginna G Laport; Wen-Kai Weng; Jonathan E Benjamin; Joanna Schaenman; Janice Brown; Jessica Ramirez; James L Zehnder; Robert S Negrin; David B Miklos
Journal:  Blood       Date:  2012-05-04       Impact factor: 22.113
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.